Incyte (NASDAQ: INCY) announced a partnership with Enable Injections to develop its investigational mutant calreticulin monoclonal antibody using Enable's enFuse On-Body Delivery System, according to a press release.

Under the agreement, Incyte obtains worldwide exclusive rights to use the enFuse technology with its mutCALR-targeted therapy INCA033989 for essential thrombocythemia and myelofibrosis treatment. The deal includes potential expansion to additional assets and indications.

Incyte will pay Enable an upfront technology access fee, potential research and development milestones, commercial milestones and a transfer price for clinical and commercial supply of enFuse devices. Financial terms were not disclosed.

INCA033989 targets calreticulin mutations, described as the second most common oncogenic driver of myeloproliferative neoplasms. The enFuse system delivers large volumes of medications subcutaneously rather than intravenously, allowing for potential at-home administration.

"We are continually seeking new ways to enhance care and improve the overall treatment pathway for patients," said Bill Meury, Incyte's president and chief executive officer.

Enable's enFuse technology received U.S. Food and Drug Administration approval in 2023 and European Union Medical Device Regulation CE Mark approval in March 2025. The Cincinnati-based company develops wearable drug delivery technology for pharmaceutical and biologic therapeutics.

Incyte, headquartered in Wilmington, Delaware, focuses on oncology and inflammation treatments. The company operates in North America, Europe and Asia.